Background: To estimate conditional survival (CS) for high-risk early-stage cervical cancer patients with lymph node metastasis after hysterectomy. Methods: 1964 T_1-2N₁M₀ cervical cancer patients who underwent primary hysterectomy from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Result (SEER) Program. Univariate and multivariate cox regression analysis were used to identify independent risk factors. 5-year conditional disease-specific survival (CDS5) and 5-year conditional relative survival (CRS5) were estimated. CDS5 and CRS5 stratified by risk factors were further calculated. Results: CDS5 and CRS5 increased from 71.0% and 73.7% at 0-year to 89.2% and 91.7% at 5-year, respectively. Inversely, the actuarial disease-specific survival and RS dropped from 71.0% and 73.7% at 5-year to 63.3% and 67.6% at 10-year, respectively. Patients with unfavorable factors had a bigger gap between actuarial survival and CS. Both CDS5 and CRS5 curves across stratas of each prognostic factor had a tendency to level off with time elapsing. Notably, CRS5 couldn't exceed 95% even after 5-year follow-up except for patients with grade I disease (CRS5 at 5-year: 100%) or tumor size less than 2 cm (CRS5 at 5-year: 96%). Conclusion: CS increased over time while actuarial survival decreased as time passed. Patients with unfavorable factors had bigger improvement in CS than those with favorable factors. Excess mortality still existed in these patients after 5-year follow-up compared to the general population except for patients with grade I disease or tumor size <2 cm, who might gradually decrease follow-up times after 5-year.

背景：评估高危早期宫颈癌子宫切除术后淋巴结转移患者的条件生存率（CS）。方法：从监测、流行病学和最终结果（SEER）项目中提取2004年至2015年接受原发性子宫切除术的1964例T _1-2 N ₁ M ₀宫颈癌患者。使用单变量和多变量 Cox 回归分析来确定独立的危险因素。估计了 5 年条件性疾病特异性生存期 (CDS5) 和 5 年条件性相对生存期 (CRS5)。进一步计算了按风险因素分层的 CDS5 和 CRS5。结果：CDS5 和 CRS5 从 0 年时的 71.0% 和 73.7% 分别增加到 5 年时的 89.2% 和 91.7%。相反，精算疾病特异性生存率和 RS 从 5 年的 71.0% 和 73.7% 分别下降到 10 年的 63.3% 和 67.6%。有不利因素的患者精算生存率与CS之间的差距较大。CDS5 和 CRS5 曲线在每个预后因素的各层中都有随着时间流逝而趋于平稳的趋势。值得注意的是，即使在 5 年的随访后，CRS5 也不能超过 95%，除了 I 级疾病（5 年 CRS5：100%）或肿瘤大小小于 2 cm（5 年 CRS5：96%）的患者）。结论：CS随着时间的推移而增加，而精算生存率随着时间的推移而下降。有不利因素的患者CS比有有利因素的患者有更大的改善。与一般人群相比，这些患者在 5 年随访后仍然存在过高的死亡率，但 I 级疾病或肿瘤大小 <2 cm 的患者可能会在 5 年后逐渐减少随访时间。